annb0t
Top 20
SYDNEY, July 12, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the launch of its Scientific Advisory Board (SAB). The new SAB consists of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer. Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)
Key Points
SAB will advise and guide Kazia as paxalisib moves towards ...
>>> Read more: KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
Key Points
SAB will advise and guide Kazia as paxalisib moves towards ...
>>> Read more: KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER
